Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy

Manylion Llyfryddiaeth
Prif Awduron:	Fairclough, R, Potter, A, Powell, D, Squire, S, Bland, M, Bareja, A, Tinsley, J, Davies, K
Fformat:	Conference item
Cyhoeddwyd:	2008

Eitemau Tebyg

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
gan: Fairclough, R, et al.
Cyhoeddwyd: (2012)

Utrophin in the therapy of Duchenne Muscular Dystrophy
gan: Potter, A, et al.
Cyhoeddwyd: (2006)

Utrophin upregulation in Duchenne muscular dystrophy.
gan: Hirst, R, et al.
Cyhoeddwyd: (2005)

Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research
gan: Bareja, A
Cyhoeddwyd: (2011)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
gan: Fairclough, R, et al.
Cyhoeddwyd: (2014)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
gan: Guiraud, S, et al.
Cyhoeddwyd: (2019)

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
gan: Chancellor, DR, et al.
Cyhoeddwyd: (2011)

Progress in therapy for Duchenne muscular dystrophy.
gan: Fairclough, R, et al.
Cyhoeddwyd: (2011)

Progress in therapy for Duchenne muscular dystrophy
gan: Fairclough, R, et al.
Cyhoeddwyd: (2011)

Utrophin upregulation in DMD therapy: current status and new tools for the future
gan: Fairclough, R, et al.
Cyhoeddwyd: (2011)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
gan: Perkins, K, et al.
Cyhoeddwyd: (2002)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
gan: Tinsley, J, et al.
Cyhoeddwyd: (2013)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
gan: Perkins, K, et al.
Cyhoeddwyd: (2000)

Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy
gan: Sewry, C, et al.
Cyhoeddwyd: (2004)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
gan: Griffin, J, et al.
Cyhoeddwyd: (2002)

Utrophin in therapy of Duchenne muscular distrophy
gan: Fisher, R
Cyhoeddwyd: (2001)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
gan: Janghra, N, et al.
Cyhoeddwyd: (2016)

Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
gan: Narinder Janghra, et al.
Cyhoeddwyd: (2016-01-01)

Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
gan: Wilkinson, I
Cyhoeddwyd: (2019)

Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy
gan: Ruo Wu, et al.
Cyhoeddwyd: (2022-11-01)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
gan: Perkins, K, et al.
Cyhoeddwyd: (2018)

From diagnosis to therapy in Duchenne muscular dystrophy
gan: Babbs, A, et al.
Cyhoeddwyd: (2020)

Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.
gan: Fairclough, R, et al.
Cyhoeddwyd: (2013)

Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation
gan: Fairclough, R, et al.
Cyhoeddwyd: (2010)

Metabolic dysfunction and altered mitochondrial dynamics in the utrophin-dystrophin deficient mouse model of duchenne muscular dystrophy.
gan: Meghna Pant, et al.
Cyhoeddwyd: (2015-01-01)

Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy.
gan: Fairclough, R, et al.
Cyhoeddwyd: (2012)

The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
gan: Perkins, K, et al.
Cyhoeddwyd: (2001)

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
gan: Tinsley, J, et al.
Cyhoeddwyd: (2011)

Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy.
gan: Valeria Ricotti, et al.
Cyhoeddwyd: (2016-01-01)

Second-generation compound for the modulation of utrophin in the therapy of DMD
gan: Guiraud, S, et al.
Cyhoeddwyd: (2015)

Regenerative biomarkers for Duchenne muscular dystrophy
gan: Guiraud, S, et al.
Cyhoeddwyd: (2019)

Duchenne Muscular Dystrophy
gan: J Gordon Millichap
Cyhoeddwyd: (1989-05-01)

Regenerative biomarkers for Duchenne muscular dystrophy
gan: Simon Guiraud, et al.
Cyhoeddwyd: (2019-01-01)

Therapeutic approaches for Duchenne muscular dystrophy
gan: Roberts, TC, et al.
Cyhoeddwyd: (2023)

PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD)
gan: Kasturi Sengupta, et al.
Cyhoeddwyd: (2020-12-01)

Nitric Oxide and l-Arginine Cause an Accumulation of Utrophin at the Sarcolemma: A Possible Compensation for Dystrophin Loss in Duchenne Muscular Dystrophy
gan: Emmanuel Chaubourt, et al.
Cyhoeddwyd: (1999-12-01)

Duchenne muscular dystrophy - past, present and future
gan: Davies, K
Cyhoeddwyd: (2002)

Cardiac therapies for Duchenne muscular dystrophy
gan: Md Nur Ahad Shah, et al.
Cyhoeddwyd: (2023-07-01)

Rehabilitation therapy of Duchenne muscular dystrophy
gan: Cheng ZHANG, et al.
Cyhoeddwyd: (2012-06-01)

Pharmacological advances for treatment in Duchenne muscular dystrophy
gan: Guiraud, S, et al.
Cyhoeddwyd: (2017)